Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Squalamine with Hormone Therapy in Prostate Cancer
NCT00244920Phase 2Withdrawn
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jan 2002
- Primary completion
- Jun 2007
- Modality
- Multivalent & Scaffold-Based Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 2, randomised, open-label trial of squalamine in prostate cancer (PCa), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Tumor response in terms of tumor volume, Tumor response in terms of conventional histopathology and 1 more. Planned start Jan 2002; status: withdrawn.
02
Drugs
squalamine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00244920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00244920.